iSpecimen completes first phase of digital transformation program

Published 21/08/2025, 13:20
iSpecimen completes first phase of digital transformation program

WOBURN, Massachusetts - iSpecimen Inc. (NASDAQ:ISPC), an online marketplace for human biospecimens, announced Thursday it has completed the first milestone in its digital transformation program powered by Salestack Solutions. The company, which generated $5.91 million in revenue over the last twelve months with a concerning 43.77% decline, is currently trading at $1.16 per share.

The initial phase involved installing Salestack’s platform and modernizing the company’s infrastructure to support the iSpecimen Marketplace. The implementation includes Infrastructure-as-Code capabilities, unified storage workflows, and multi-cloud deployment options.

"The successful completion of Milestone 1 is a major step forward in iSpecimen’s mission to create the most efficient and secure marketplace in our industry," said Robert Lim, CEO of iSpecimen, according to the company’s press release.

The upgraded infrastructure is designed to improve system reliability through multi-cloud architecture, enhance security via automated safeguards, and accelerate development cycles for faster feature delivery.

With the first milestone complete, iSpecimen plans to advance to Milestone 2, which will focus on integrating all parts of the company’s business with the Salestack platform to improve operational efficiency.

iSpecimen operates an online marketplace that connects scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical research.

The announcement contains forward-looking statements regarding the expected benefits of the digital transformation, with actual results potentially differing from projections based on various factors including market conditions and the company’s ability to meet future milestones.

In other recent news, iSpecimen Inc. announced the pricing of an underwritten public offering, aiming to raise approximately $4 million in gross proceeds by selling 5,714,283 shares of common stock at $0.70 per share. This offering is expected to close on July 25, 2025, with WestPark Capital, Inc. serving as the sole book-runner for the transaction. Additionally, iSpecimen secured approximately $1.75 million through a securities purchase agreement with accredited investors, issuing 1,559,828 shares of common stock or pre-funded warrants at $1.122 per share. The company also revealed plans to establish a digital asset treasury reserve of up to $200 million based on the Solana blockchain ecosystem. For this initiative, iSpecimen has retained WestPark Capital as a financial advisor and BlockArrow, a digital asset management firm, to guide the strategy and compliance. These developments indicate a strategic move by iSpecimen to bolster its financial standing and explore innovative financial avenues.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.